International Journal of Gynecological Cancer最新文献

{"title":"<i>TERT</i> promoter mutations and survival outcomes in adult-type granulosa cell tumors.","authors":"Allison L Brodsky, Alejandra Flores Legarreta, Bryan M Fellman, Deanna Glassman, Jeffrey How, Veena Vuttaradhi, Anil K Sood, Lois Michelle Ramondetta, David Gershenson, Robert Tyler Hillman","doi":"10.1136/ijgc-2024-005837","DOIUrl":"10.1136/ijgc-2024-005837","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate survival outcomes among patients with adult-type granulosa cell tumors who have telomerase reverse transcriptase (<i>TERT</i>) promoter mutations.</p><p><strong>Methods: </strong>This is a retrospective cohort study using the MD Anderson Rare Gynecologic Malignancy Registry. Patients with adult granulosa cell tumors who underwent molecular testing for <i>TERT</i> promoter and <i>FOXL2</i> c.C402G mutations were included. We used descriptive statistics to compare demographic and clinical variables and estimated progression-free and overall survival with Kaplan-Meier curves. Cox proportional hazards regression and log-rank tests were employed for comparisons, with multivariable analyses adjusting for various factors.</p><p><strong>Results: </strong>Among 70 patients, 28 (40%) had <i>TERT</i>+ tumors. The median age at diagnosis was 40 years (range 12-71) for <i>TERT</i>- patients and 46 years (range 25-76) for <i>TERT</i>+ patients. At diagnosis, 22 (63%) of 35 <i>TERT</i>- patients were stage I, 10 (29%) stage II, and 3 (9%) stage III, while in the <i>TERT</i>+ group, 17/23 (74%) were stage I, 3 (13%) stage II, and 3 (13%) stage II. Univariable analysis showed no difference in time from diagnosis to first recurrence (<i>p</i>=0.19) and from first recurrence to second recurrence (<i>p</i>=0.24) based on tumor <i>TERT</i> status. The median time from first to second recurrence in the <i>TERT</i>- group was 27.3 months (95% CI 14.1 to 40.0) and in the <i>TERT</i>+ group was 14.8 months (95% CI 8.1 to 21.0). There was no observed difference in overall survival between the groups (HR=0.53; 95% CI 0.19 to 1.45; <i>p</i>=0.21). Multivariable analysis adjusting for age at diagnosis, <i>TERT</i> promoter mutation status, systemic chemotherapy, and stage demonstrated a significant difference in progression-free survival based on <i>TERT</i> mutation status (HR=2.89; 95% CI 1.32 to 6.36).</p><p><strong>Conclusions: </strong>After adjustment for covariates, patients with adult granulosa cell tumors and <i>TERT</i>+ tumors had shorter progression-free survival after first recurrence. <i>TERT</i> promoter mutations may identify a subset of patients with recurrent adult granulosa cell tumors and less favorable outcomes.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of tumor-infiltrating lymphocytes in vulvovaginal melanoma.","authors":"Margaux Vanbockstael, Guillaume Bataillon, Mathilde Morisseau, Gwenael Ferron, Justine Attal, Thomas Meresse, Emilie Tournier, Yann Tanguy Le Gac, Cécile Pages, Alejandra Martinez","doi":"10.1136/ijgc-2024-005359","DOIUrl":"https://doi.org/10.1136/ijgc-2024-005359","url":null,"abstract":"<p><strong>Objective: </strong>To assess the relation between immune microenvironment, survival, and clinicopathological characteristics.</p><p><strong>Methods: </strong>This study was a retrospective, single-center, observational study. Patients with a vulvovaginal melanoma and available archived material were included. All cases underwent pathology review, tumor-infiltrating lymphocyte quantification, and next-generation sequencing analysis, when feasible. Clinical data included demographic, treatment, and prognostic data.</p><p><strong>Results: </strong>Forty-two patients were selected during the study period, but 13 were finally excluded owing to unavailable formalin-fixed, paraffin-embedded material or unknown follow-up data. Twelve of 19 cases (63.2%) had at least one genetic mutation, 3/18 (16.7%) had BRAF, 3/18 (16.7%) had c-KIT mutation, and 4/17 (23.5%) had NRAS mutations. High stromal tumor-infiltrating lymphocytes were identified in 13/28 patients (46.4%), and brisk tumor-infiltrating lymphocytes in 17/28 patients (60.7%). A density of stromal tumor-infiltrating lymphocytes >40% and brisk distribution were the single clinicopathologic factor associated with increased disease-free survival.</p><p><strong>Conclusion: </strong>The study showed that brisk tumor-infiltrating lymphocytes and stromal tumor-infiltrating lymphocytes were a marker for disease progression, and for response to immunotherapy strategies. To validate these findings on a larger scale, further research is warranted through a multicenter study with a larger cohort and additional genetic and translational analysis.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First robotic radical trachelectomy for cervical cancer using the Hugo RAS platform.","authors":"Renato Moretti-Marques, Vanessa Alvarenga-Bezerra, Pedro Ernesto de Cillo, Danielle Y Akaishi, Jeancarllo de Sousa Silva, Nam Jin Kim","doi":"10.1136/ijgc-2024-005895","DOIUrl":"https://doi.org/10.1136/ijgc-2024-005895","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary cytoreductive surgery for recurrent endometrial cancer: can we predict the future?","authors":"Fionán Donohoe, Mario M Leitao","doi":"10.1136/ijgc-2024-006226","DOIUrl":"https://doi.org/10.1136/ijgc-2024-006226","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to optimize and evaluate diversity in gynecologic cancer clinical trials: statements from the GCIG Barcelona Meeting.","authors":"Jalid Sehouli, Jolijn Boer, Alison H Brand, Amit M Oza, Jennifer O'Donnell, Katherine Bennett, Ros Glaspool, Chee Khoon Lee, Josee-Lyne Ethier, Philipp Harter, Veronika Seebacher-Shariat, Ting-Chang Chang, Paul A Cohen, Toon van Gorp, Adriana Chavez-Blanco, Stephen Welch, Hanna Hranovska, Sharon O'Toole, Christianne A R Lok, Ainhoa Madariaga, Jose Alejandro Rauh-Hain, Alejandro Perez Fidalgo, David Tan, Judith Michels, Bhavana Pothuri, Noriko Fujiwara, Ora Rosengarten, Hiroshi Nishio, Se Ik Kim, Asima Mukopadhyay, Elisa Piovano, Sabrina Chiara Cecere, Elise C Kohn, Uma Mukherjee, Sara Nasser, Kristina Lindemann, Jennifer Croke, Xiaojun Chen, Franziska Geissler, Michael A Bookman","doi":"10.1136/ijgc-2024-005982","DOIUrl":"https://doi.org/10.1136/ijgc-2024-005982","url":null,"abstract":"<p><p>Findings from clinical trials have led to advancement of care for patients with gynecologic malignancies. However, restrictive inclusion of patients into trials has been widely criticized for inadequate representation of the real-world population. Ideally, patients enrolled in clinical trials should represent a broader population to enhance external validity and facilitate translation of outcomes across all relevant groups. Specifically, there has been a systematic lack of data for underrepresented groups, with many studies failing to report or differentiate study participants based on sociodemographic domains, such as race and ethnicity. As such, the impact of treatment in these underrepresented groups is poorly understood, and clinical outcomes according to various sociodemographic factors are infrequently assessed. Inclusion of diverse trial participants, with different racial and ethnic background, is essential for the understanding of factors that may impact clinical outcomes. Therefore, we conducted a multi-national meeting of clinical trial groups and industry with the goal of increasing equity, diversity, and inclusion in gynecologic cancer clinical trials and to address barriers to recruitment, participation, and harmonization of data collection and reporting. These Gynecologic Cancer Intergroup (GCIG) statements present recommendations and strategies for the gynecologic cancer research community to improve equity, diversity, and inclusion in gynecologic cancer clinical trials.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"34 11","pages":"1677-1684"},"PeriodicalIF":4.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of glutaminase expression with immune-suppressive tumor microenvironment, clinicopathologic features, and clinical outcomes in endometrial cancer.","authors":"Shiho Asaka, Neha Verma, Ting-Tai Yen, Jessica L Hicks, Hiro Nonogaki, Yao-An Shen, Jiaxin Hong, Ryoichi Asaka, Angelo M DeMarzo, Tian-Li Wang, Ie-Ming Shih, Stephanie Gaillard","doi":"10.1136/ijgc-2024-005920","DOIUrl":"10.1136/ijgc-2024-005920","url":null,"abstract":"<p><strong>Objective: </strong>Increased glutamine metabolism by cancer cells via upregulation of the drug-targetable enzyme glutaminase may contribute to an immune-suppressive tumor microenvironment. Inhibiting glutamine metabolism can not only suppress tumor growth, but also enhance tumor-specific immunity. We investigated the relationship between glutaminase expression, the immune tumor microenvironment, and clinicopathologic features in endometrial cancer.</p><p><strong>Methods: </strong>Tissue microarrays constructed from 87 primary endometrial cancer specimens were stained by immunohistochemistry for glutaminase, c-Myc, mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), mutS homolog 6 (MSH6), postmeiotic segregation increased 2 (PMS2), estrogen receptor (ER), progresterone receptor (PR), CD8, FoxP3, CD68, programmed cell death protein 1 (PD-1), and programmed cell death ligand 1 (PD-L1). We compared the immune tumor microenvironment and clinicopathologic features between glutaminase-high (H-score≥median) versus glutaminase-low (H-score<median) endometrial cancers. We also evaluated data from The Cancer Genome Atlas (TCGA) for 527 endometrial cancer patients in whom RNA-Seq for glutaminase expression was performed and compared long-term clinical outcomes between glutaminase-high (RNA-Seq Z-score≥median) versus glutaminase-low (RNA-Seq score<median) patients.</p><p><strong>Results: </strong>In the tissue microarray analysis, glutaminase expression was positively correlated with c-Myc expression (r=0.4226, p<0.0001). Glutaminase-high endometrial cancers were associated with non-endometrioid histology (p=0.0001), high histologic grade (p=0.0004), myometrial invasion (p=0.017), advanced stage (p=0.012), increased FoxP3⁺ regulatory T cells (p=0.008), increased CD68⁺ tumor-associated macrophages (p=0.010), and higher PD-L1 combined positive scores (p=0.043). In the TCGA analysis, glutaminase-high (RNA-Seq Z-score≥median) patients showed worse overall (p=0.004) and progression-free (p=0.032) survival than glutaminase-low (RNA-Seq score<median) patients.</p><p><strong>Conclusions: </strong>Our findings indicate that increased glutaminase expression is associated with an immune-suppressive tumor microenvironment, poor clinicopathologic features, and worse long-term outcomes in patients with endometrial cancer.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"1737-1744"},"PeriodicalIF":4.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gynecologic oncology surgery maneuvers applied to reduce blood loss in laparoscopic myomectomy: description of the technique in 10 steps.","authors":"Enrique Chacon, I Perez-Palacio, J Gonzalez de Canales, Nabil Manzour, Jose Angel Minguez, Luis Chiva","doi":"10.1136/ijgc-2024-005750","DOIUrl":"https://doi.org/10.1136/ijgc-2024-005750","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":""},"PeriodicalIF":4.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender equality, diversity, and inclusion among gynaecologic oncologists: European Network of Young Gynae Oncologists (ENYGO)-European Society of Gynaecological Oncology (ESGO) project.","authors":"Tanja Nikolova, Esra Bilir, Nicolò Bizzarri, Christina Fotopoulou, Toon van Gorp, Joanna Kacperczyk-Bartnik, Zoia Razumova, Aleksandra Natalia Strojna, Ane Gerda Eriksson, Maja Pakiz, Mansoor Raza Mirza, Anna Fagotti, Nicole Concin","doi":"10.1136/ijgc-2024-005697","DOIUrl":"10.1136/ijgc-2024-005697","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"1685-1690"},"PeriodicalIF":4.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting outcomes in malignant ovarian germ cell tumors using the modified International Germ Cell Cancer Collaborative Group classification system.","authors":"Xinyue Zhang, Jie Yang, Yang Xiang, Ming Wu, Dongyan Cao, Jinhui Wang, Jiaxin Yang","doi":"10.1136/ijgc-2024-005489","DOIUrl":"10.1136/ijgc-2024-005489","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of our study was to evaluate the feasibility of the modified International Germ Cell Cancer Collaborative Group risk classification system in Chinese female patients with malignant ovarian germ cell tumors and to identify predictive factors to enhance the risk classification system.</p><p><strong>Methods: </strong>In this retrospective cohort analysis, patients with malignant ovarian germ cell tumors who received surgery with/without chemotherapy were included. These patients had been followed-up by Peking Union Medical College Hospital between 2011 to 2020. Patients without complete medical records or no follow-up information were excluded.</p><p><strong>Results: </strong>The study enrolled a total of 271 patients. The risk model classified 106 (39.1%) patients as good-, 84 (31%) as intermediate-, and 81 (29.9%) as poor-risk. With a median follow-up time of 34 months (range 2-147), 48 (17.7%) recurrence and 16 (5.9%) deaths were observed. The risk classification significantly correlated with 3 year disease-free survival and overall survival (log rank p<0.001 and p=0.003, respectively). The survival outcomes of disease-free survival and overall survival were not statistically different among risk groups in patients who received neoadjuvant chemotherapy (log rank p=0.77 and 0.41, respectively). Univariate and multivariable analysis showed that tumor stage (p=0.033, hazard ratio (HR) 2.05, 95% confidence interval (CI) 1.06 to 3.96) was significantly associated with relapse or progression of disease. Patients over age 40 years exhibited a poor prognosis.</p><p><strong>Conclusion: </strong>The modified International Germ Cell Cancer Collaborative Group risk classification system was efficacious in patients with malignant ovarian germ cell tumors and was significantly associated with disease-free survival and overall survival. Risk assessment after neoadjuvant chemotherapy may be more predictive than stratification at initial diagnosis. Age and tumor stage were definitive prognostic factors for germ cell tumors, which may need to be incorporated in the stratification system.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"1745-1752"},"PeriodicalIF":4.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe.","authors":"Kathleen N Moore, Mansoor R Mirza, Charlie Gourley, Sandro Pignata, Domenica Lorusso, Bradley J Monk, Jalid Sehouli, Jeanne M Schilder, Nathalie D'Esquermes, Antonio González-Martín","doi":"10.1136/ijgc-2024-005405","DOIUrl":"10.1136/ijgc-2024-005405","url":null,"abstract":"<p><strong>Objectives: </strong>Real-world data evaluating how approvals of novel treatment regimens for ovarian cancer have impacted the treatment paradigm, including first-line maintenance, are lacking. This analysis aimed to describe treatment patterns for advanced epithelial ovarian cancer in Europe and the USA in the first-line maintenance setting. Patient characteristics, biomarker testing rates, and drivers of treatment choice were also evaluated.</p><p><strong>Methods: </strong>A retrospective chart review study of electronic medical records in Europe and the USA was conducted for patients diagnosed with epithelial ovarian cancer (June 1, 2017-May 31, 2020), in line with Healthcare Market Research guidelines. Eligible physicians extracted data from electronic medical records by completing standardized patient record forms, including questions on patient involvement in treatment decisions. Patients with advanced (stage III/IV) disease were stratified by country and diagnosis date to provide information on treatment patterns.</p><p><strong>Results: </strong>Patient record forms for 7072 patients with epithelial ovarian cancer were completed by 416 physicians; 5386 patients had stage III/IV ovarian cancer. Over time, the percentage of patients who were tested for <i>BRCA</i> mutations or homologous recombination deficiency increased. Patient preference was documented as a reason for treatment selection in approximately one-sixth of cases in the first-line adjuvant and first-line maintenance settings. The use of first-line maintenance poly(ADP-ribose) polymerase inhibitor monotherapy increased over time, while the use of vascular endothelial growth factor inhibitor monotherapy decreased.</p><p><strong>Conclusions: </strong>This real-world study showed that treatment patterns for advanced epithelial ovarian cancer varied by country. Rates of physician-reported patient involvement in treatment decisions in the first-line adjuvant and maintenance treatment settings for ovarian cancer were low, highlighting an unmet need for initiatives to improve patient involvement in shared decision-making regarding maintenance therapy selection.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"1753-1760"},"PeriodicalIF":4.1,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}